Influenza Vaccine Market - North America to Dominate the Market with High Margin

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

Get PDF with Technological trends at https://www.futuregenicreports.com/Request-Sample/100262

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.

Major and Promising Vaccine covered in the report are as follows:

1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax

Obtain Report Details with Technological advancement at https://www.futuregenicreports.com/Reports/Influenza-Vaccine-Market

Key Companies Covered in the Report are as follows

1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate

About Future Genic Reports

Future Generic Reports is a market research and consulting organization, offering premium collection of market research reports, custom research and consulting services to corporations, no-profit organizations and government institutions across the globe.

The wide range of information is presented by a team of well-trained researchers of specific sectors through exhaustive research. We deliver premier market research services that cover all industry verticals, including chemicals and material, automotive, healthcare, electronics & semiconductor, food and beverage, pharmaceuticals and technology and media.

We believe in building an eternal bond with our clients through offering them inclusive research study meeting their specific requirements. Our services are tailored specifically to our clients by proposing them the potential outcome, based on our in-depth analysis and insights for exploring the growth strategies through providing the best possible decision for quality production.

Contact Us:

244, Madison Avenue
New York City, NY - 10016
United States
Toll Free +1- 844-445-2861
E-mail: sales@futuregenicreports.com

This release was published on openPR.